News Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:20 05/06/2026 BST			5-day change	1st Jan Change
71.50 ^GBX	+2.14%		-9.49%	+23.28%

06-05	Avacta Group raises GBP9 million for bond repayments	AN
06-05	Avacta Therapeutics Raises GBP9 Million from Share Issue	MT

All News

Mentions Relevance

06-05	Avacta Group raises GBP9 million for bond repayments	AN
06-05	Avacta Therapeutics Raises GBP9 Million from Share Issue	MT
06-01	Avacta Therapeutics Presents Updated Clinical Data for Ava6000 in Salivary Gland Cancers At Asco 2026	CI
06-01	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	GL
06-01	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	AQ
05-29	Avacta : Annual Report and Accounts for the year ending 31 December 2025	PU
05-29	Avacta Group plc Announces Board Changes	CI
05-29	Avacta Therapeutics Names Chairman Designate	MT
05-25	Avacta Group Plc - Special Call
05-22	Avacta Group Plc, 2025 Earnings Call, May 19, 2026
05-19	Avacta Group annual loss widens as cancer treatment trial results loom	AN
05-19	Avacta Therapeutics reports group revenues of £6.31 million for year ended December 31, 2025	RE
05-19	Avacta Group continues to explores multiple commercial opportunities with strategic partners	RE
05-19	Unaudited Preliminary Results for the Year Ended December 31, 2025	GL
05-19	Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	PU
05-06	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	GL
05-06	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
04-21	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform	GL
04-21	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026	CI
04-14	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders	GL
04-09	Avacta hails "important milestones" in start of "transformative" year	AN
04-08	Avacta : Announces 2026 Science Day Event	PU
03-31	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate	GL
03-31	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd	CI